NASDAQ:OLMA Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis → Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad) Free OLMA Stock Alerts $13.08 -0.05 (-0.38%) (As of 02:46 PM ET) Add Compare Share Share Today's Range$12.64▼$13.4950-Day Range$8.73▼$13.9952-Week Range$7.37▼$17.79Volume583,971 shsAverage Volume876,550 shsMarket Capitalization$731.56 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Olema Pharmaceuticals alerts: Email Address Olema Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.3% Upside$22.00 Price TargetShort InterestBearish15.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 16 Articles This WeekInsider TradingSelling Shares$612,450 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.30) to ($2.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector695th out of 904 stocksPharmaceutical Preparations Industry325th out of 427 stocks 3.5 Analyst's Opinion Consensus RatingOlema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOlema Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Olema Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.27% of the outstanding shares of Olema Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOlema Pharmaceuticals has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Olema Pharmaceuticals has recently increased by 1.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOlema Pharmaceuticals does not currently pay a dividend.Dividend GrowthOlema Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OLMA. Previous Next 2.5 News and Social Media Coverage News SentimentOlema Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Olema Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest8 people have searched for OLMA on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $612,450.00 in company stock.Percentage Held by Insiders19.40% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Olema Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.30) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Olema Pharmaceuticals is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Olema Pharmaceuticals is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOlema Pharmaceuticals has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Olema Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DeFi Distribution[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially profit from this trillion-dollar niche WITHOUT buying a single coin, NFT or investing in ANYTHING.Grab the PDF here for free: About Olema Pharmaceuticals Stock (NASDAQ:OLMA)Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Read More OLMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OLMA Stock News HeadlinesJune 6, 2024 | insidertrades.comCyrus Harmon Sells 5,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) StockJune 8 at 5:48 AM | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down to $13.92June 8 at 2:12 AM | americanbankingnews.comAnalysts Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) PT at $22.00June 6, 2024 | americanbankingnews.comCyrus Harmon Sells 15,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) StockJune 6, 2024 | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 3.2% on Insider SellingJune 5, 2024 | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Given Buy Rating at HC WainwrightJune 4, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 28, 2024 | globenewswire.comOlema Oncology to Participate in Upcoming Investor Conferences in JuneMay 21, 2024 | barrons.comOlema Pharmaceuticals Inc.May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib CombinationMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Olema Pharmaceuticals Amid Promising Clinical Trial Results for Breast Cancer TherapyMay 16, 2024 | markets.businessinsider.comBuy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals’ Drug Combination in Clinical StudiesMay 16, 2024 | markets.businessinsider.comPromising Combination Therapy Drives Buy Rating for Olema PharmaceuticalsMay 15, 2024 | markets.businessinsider.comPromising Clinical Trial Results Bolster Buy Rating for Olema PharmaceuticalsMay 15, 2024 | globenewswire.comOlema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer CongressMay 10, 2024 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial PositionMay 9, 2024 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals: Financial Stability and Promising Drug Development Fuel Positive OutlookMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis CollaborationMay 8, 2024 | investorplace.comOLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024May 8, 2024 | globenewswire.comOlema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comOlema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressMay 2, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | globenewswire.comOlema Oncology to Participate in Upcoming Investor Conferences in MayApril 21, 2024 | finance.yahoo.comOlema Pharmaceuticals, Inc. (OLMA)April 12, 2024 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive EdgeSee More Headlines Receive OLMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/10/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OLMA CUSIPN/A CIK1750284 Webwww.olema.com Phone650-243-5555FaxN/AEmployees74Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$30.00 Low Stock Price Target$18.00 Potential Upside/Downside+67.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.87% Return on Assets-39.30% Debt Debt-to-Equity RatioN/A Current Ratio9.61 Quick Ratio9.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book2.85Miscellaneous Outstanding Shares55,930,000Free Float45,083,000Market Cap$735.48 million OptionableOptionable Beta2.05 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Sean P. Bohen M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1MMr. Shane William Charles Kovacs M.B.A. (Age 50)Chief Operating & Financial Officer Comp: $726.17kDr. Naseem Zojwalla M.D. (Age 51)Chief Medical Officer Comp: $775.48kMr. Geoffrey MogilnerVice President of Investor Relations & CommunicationsMs. Julie DexterSenior VP & Head of PeopleDr. David C. Myles Ph.D. (Age 61)Chief Discovery & Non-Clinical Development Officer Comp: $200kMs. Demiana Faltaos Ph.D.Pharm.D., VP & Head of Clinical PharmacologyMr. John B. Moriarty Jr. (Age 56)J.D., Corporate Secretary Comp: $434.32kMs. Sasha Austin CPAVP of Finance & ControllerMore ExecutivesKey CompetitorsMoonLake ImmunotherapeuticsNASDAQ:MLTXACADIA PharmaceuticalsNASDAQ:ACADStructure TherapeuticsNASDAQ:GPCRJanux TherapeuticsNASDAQ:JANXTG TherapeuticsNASDAQ:TGTXView All CompetitorsInsiders & InstitutionsCyrus HarmonSold 5,000 sharesTotal: $54,650.00 ($10.93/share)Cyrus HarmonSold 15,000 sharesTotal: $141,150.00 ($9.41/share)Walleye Trading LLCSold 1,300 shares on 5/17/2024Ownership: 0.000%Janus Henderson Group PLCBought 521,562 shares on 5/16/2024Ownership: 2.184%Jacobs Levy Equity Management Inc.Sold 74,740 shares on 5/16/2024Ownership: 0.134%View All Insider TransactionsView All Institutional Transactions OLMA Stock Analysis - Frequently Asked Questions Should I buy or sell Olema Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OLMA shares. View OLMA analyst ratings or view top-rated stocks. What is Olema Pharmaceuticals' stock price target for 2024? 7 Wall Street research analysts have issued 1-year price objectives for Olema Pharmaceuticals' shares. Their OLMA share price targets range from $18.00 to $30.00. On average, they predict the company's share price to reach $22.00 in the next year. This suggests a possible upside of 67.3% from the stock's current price. View analysts price targets for OLMA or view top-rated stocks among Wall Street analysts. How have OLMA shares performed in 2024? Olema Pharmaceuticals' stock was trading at $14.03 on January 1st, 2024. Since then, OLMA stock has decreased by 6.3% and is now trading at $13.15. View the best growth stocks for 2024 here. When is Olema Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our OLMA earnings forecast. How were Olema Pharmaceuticals' earnings last quarter? Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) announced its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.03. What ETF holds Olema Pharmaceuticals' stock? Virtus LifeSci Biotech Clinical Trials ETF holds 7,300 shares of OLMA stock, representing 0.91% of its portfolio. When did Olema Pharmaceuticals IPO? Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO. Who are Olema Pharmaceuticals' major shareholders? Olema Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.30%), Janus Henderson Group PLC (2.18%), Acadian Asset Management LLC (0.18%), Jacobs Levy Equity Management Inc. (0.13%), Swiss National Bank (0.13%) and ClariVest Asset Management LLC (0.11%). Insiders that own company stock include Biocapital Advisors L Paradigm, Bvf Partners L P/Il, Cyrus Harmon, David C Myles, G Walmsley Graham, Kinney Horn, Naseem Zojwalla and Sean Bohen. View institutional ownership trends. How do I buy shares of Olema Pharmaceuticals? Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OLMA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
